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ABSTRACT The Na1yH1 exchanger regulatory factor
(NHERF) binds to the tail of the b2-adrenergic receptor and
plays a role in adrenergic regulation of Na1yH1 exchange.
NHERF contains two PDZ domains, the first of which is
required for its interaction with the b2 receptor. Mutagenesis
studies of the b2 receptor tail revealed that the optimal
C-terminal motif for binding to the first PDZ domain of
NHERF is D-SyT-x-L, a motif distinct from those recognized
by other PDZ domains. The first PDZ domain of NHERF-2, a
protein that is 52% identical to NHERF and also known as
E3KARP, SIP-1, and TKA-1, exhibits binding preferences very
similar to those of the first PDZ domain of NHERF. The
delineation of the preferred binding motif for the first PDZ
domain of the NHERF family of proteins allows for predic-
tions for other proteins that may interact with NHERF or
NHERF-2. For example, as would be predicted from the b2
receptor tail mutagenesis studies, NHERF binds to the tail of
the purinergic P2Y1 receptor, a seven-transmembrane recep-
tor with an intracellular C-terminal tail ending in D-T-S-L.
NHERF also binds to the tail of the cystic fibrosis transmem-
brane conductance regulator, which ends in D-T-R-L. Because
the preferred binding motif of the first PDZ domain of the
NHERF family of proteins is found at the C termini of a
variety of intracellular proteins, NHERF and NHERF-2 may
be multifunctional adaptor proteins involved in many previ-
ously unsuspected aspects of intracellular signaling.
PDZ domains are conserved protein modules that mediate
protein–protein interactions (1–3). The term ‘‘PDZ’’ is derived
from the first letters in the names of the three proteins in which
these modules were originally characterized: PSD-95, Dlg, and
ZO-1. PDZ domains bind to the C-terminal tails of target
proteins, and the binding preferences of a number of PDZ
domains have been characterized (4–7). Such characterization
is useful because it allows for predictions regarding the set of
proteins to which a given PDZ domain may potentially bind.
A PDZ domain-containing protein, the Na1yH1 exchanger
regulatory factor (NHERF), has been recently characterized
(8) and found to regulate the Na1yH1 exchanger type 3
(NHE3) (8–9) via an interaction which does not involve
binding of the NHE3 C terminus to the NHERF PDZ domains
(9). The function and preferences of the two NHERF PDZ
domains were unknown until NHERF was identified as a
binding partner of the b2-adrenergic receptor (10). The inter-
action of NHERF with the b2 receptor is mediated via binding
of the first PDZ domain of NHERF to the last few amino acids
of the b2 receptor tail (10). In the present study, we charac-
terize this interaction via mutagenesis of the b2 receptor tail
and saturation NHERF-binding studies. We furthermore dem-
onstrate that NHERF-2, a close relative of NHERF, specifi-
cally binds to the b2 receptor tail and exhibits binding speci-
ficity similar to NHERF. Moreover, we demonstrate how the
binding preferences of the first PDZ domain of the NHERF
family of proteins account for previously reported interactions
involving NHERF-2 and allow for predictions regarding other
potential NHERF- and NHERF-2-binding partners, such as
the purinergic P2Y1 receptor and cystic fibrosis transmem-
brane conductance regulator (CFTR).
MATERIALS AND METHODS
NHERF PDZ1 Overlays. Hexahistidine- and S-tagged
NHERF domain 1 fusion protein (‘‘PDZ1’’; residues 1–151 of
full-length NHERF) was created via insertion of rabbit
NHERF cDNA (8) into pET-30A (Novagen) and expression
according to manufacturer’s instructions. Wild-type or mutant
human b2 receptor tails (10), as well as human P2Y1 and P2Y2
receptor tails, were expressed as glutathione S-transferase
(GST) fusion proteins and examined for NHERF binding via
a far Western blot overlay technique. Mutant b2 receptor tail
GST constructs were created by PCR amplification from
native receptor cDNA’s by using mutant sequence oligonucle-
otides and inserting the PCR products into the pGEX-2T
vector (Pharmacia); all mutations were confirmed via sequenc-
ing with an Applied Biosystems 377 automated sequencer. The
GST fusion proteins (25 mgylane) were run on 4–20% SDSy
PAGE gels (NOVEX, San Diego), blotted, and overlaid with
increasing concentrations of NHERF PDZ1 fusion protein in
2% milk and 0.1% Tween-20 in PBS (‘‘blot buffer’’) for 1 hr
at room temperature. The blots were then washed three times
with blot buffer, incubated for 1 hr at room temperature with
an horseradish peroxidase-conjugated anti-S-tag antibody
(Novagen) in blot buffer, washed three more times with blot
buffer, and visualized via chemiluminescence. To perform
saturation-binding curves, equal amounts of a given fusion
protein were loaded into multiple lanes, and the resultant blots
were cut into one-lane strips. The strips were incubated with
increasing concentrations of NHERF PDZ1 fusion protein,
and the amount of NHERF binding for each was quantified via
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scanning and analysis with the program IPLAB (Signal Analyt-
ics).
Cloning of NHERF-2. NHERF-2 was cloned from a human
lung cDNA library (CLONTECH) by amplification using
primers (59-CACCCGGAATTCGCCGCCATGGC-CGCGC-
CGGAGCCGCTGCGG and 59-CACCCGGTCGACTCAGT-
CAGCAGGCC-CCGGCAGCGA) based on the sequence for
‘‘TKA-1,’’ which was submitted to GenBank by Seedorf and
Ullrich (GenBank accession no. Z50150; unpublished results).
The species we cloned (GenBank accession no. AF035771) is
clearly the same gene product as TKA-1, E3KARP (9), and
SIP-1 (11), although none of these three sequences is identical
to any other and our sequence is slightly different from each
of them. We prepared full-length NHERF-2 as well as the two
halves of the molecule as fusion proteins by inserting amplified
fragments into pET-30A by using EcoRI and SalI (underlined
sites in primers); the ‘‘N-terminal’’ NHERF-2 construct con-
tains the first 148 amino acids and the first PDZ domain,
whereas the ‘‘C-terminal’’ construct contains the last 189
residues and the second PDZ domain.
b2 Receptor Tail-GST Overlays. Far Western overlay ex-
periments were performed by running the NHERF-2 fusion
protein samples (25 mg per lane) on 4–20% SDSyPAGE gels
(Novex) for 1 hr at 150 V and then blotting to nitrocellulose
for 40 min at 12 V. The blots were blocked in blot buffer and
incubated with the wild-type b2 receptor tail expressed as a
GST fusion protein (500 nM) in blot buffer for 1 hr at room
temperature. The blots were washed three times with blot
buffer and then incubated with an anti-GST mAb (Santa Cruz)
for l hr at room temperature to detect the overlaid b2 receptor
tail. The blots were then washed three more times with blot
buffer and incubated for l hr at room temperature with an
anti-mouse horseradish peroxidase-coupled secondary anti-
body (Amersham) in blot buffer. The blots were then washed
three more times with blot buffer, once with PBS, and then
developed with an enhanced chemiluminescence kit (Amer-
sham) and exposed to Kodak X-Omat film for varying lengths
of time.
Overlays with 35S in Vitro-Translated Protein. The following
proteins were in vitro translated by using the TNT system
(Promega) in the presence of [35S]methionine: full-length
CFTR-4, CFTR-K1468X, or fusion proteins of CFTR cloned
into the pET33b vector (Novagen) (C-terminal amino acids
1387–1480 or N-terminal amino acids 1–80). Immobilized
full-length NHERF was incubated overnight with each of the
in vitro translates (2 ml of reticulocyte lysate in 10 ml of blot
buffer), washed with blot buffer, dried, and exposed to film.
Overlays of Airway Protein. Human airway epithelial cells
were cultured at the air-liquid interface as described (12).
Triton X-100 soluble and insoluble proteins were prepared as
described (13), electrophoresed on 6–18% SDSyPAGE, and
either stained with Coomassie blue or transferred to Immo-
bilon. Immobilized proteins were blocked with blot buffer,
incubated with anti-NHERF antibody (1:1000 in blot buffer),
washed three times in blot buffer, and then incubated with
anti-rabbit horseradish peroxidase secondary antibody (Am-
ersham) (1:2500). Reactive proteins were visualized with
Super-Signal (Pierce). Identical lanes were incubated with a
32P-phosphorylated probe of the C terminus of CFTR cloned
into the pET33b vector, which contains a PKA-phosphoryla-
tion site. The protein was expressed in BL21 (DE3) cells,
purified on a Talon metal affinity column (Pharmacia), phos-
phorylated with PKA and 32P-ATP, and dialyzed to remove
nonincorporated ATP. The membrane was washed three times
with blot buffer, dried, and exposed to film.
Estimation of NHERF Cellular Concentration. Various
dilutions of full-length NHERF fusion protein were run along-
side samples of crude kidney extract on SDSyPAGE. The
samples were blotted and the amount of NHERF in each
sample was visualized by Western blotting using a previously
described anti-NHERF antibody (10) and a horseradish per-
oxidase-coupled anti-rabbit Ig secondary antibody (Amer-
sham). The resultant bands were scanned and quantified, and
the amount of NHERF in the crude tissue was derived from
the fusion protein standard curves. The per unit protein
concentration of NHERF was translated into a molar concen-
tration by assuming that 30% of the weight of the average
human kidney (150 g) is protein and that one-half of the
volume of the average human kidney (216 ml) is intracellular
volume.
RESULTS
The binding preferences of the first PDZ domain of NHERF
were determined via mutagenesis of the b2 receptor tail, the
last four amino acids of which are D-S-L-L. Previous work
demonstrated that mutation of the terminal leucine of the b2
receptor tail to alanine completely abolishes binding of
NHERF (10). Mutation of this position to six other amino
acids (Fig. 1A) revealed that the wild-type leucine is strongly
preferred. Even amino acids with similar side chains such as
isoleucine and valine yield more than fivefold reductions in
NHERF binding when they are substituted for leucine at the
end of the b2 receptor tail.
FIG. 1. NHERF preferentially binds to the motif D-SyT-x-L at the
end of target proteins. (A) Binding of the first PDZ domain of NHERF
to the b2 receptor tail is inhibited by point mutations of the final
residue of the tail. GST fusion proteins of the b2 receptor tail with
mutations at the terminal position were expressed and purified. Equal
amounts ('25 mg) were loaded on SDSyPAGE gels, blotted, and
overlaid with NHERF PDZ1 fusion protein (50 nM). The mutations
of the b2 receptor tail (D-S-L-L) are indicated in bold at the top of the
panel. (B) Point mutations at the 21, 22, and 23 positions of the b2
receptor tail differentially alter NHERF PDZ1 binding. Equal
amounts of various b2 receptor tail point mutants were loaded on an
SDSyPAGE gel, blotted, and probed for NHERF PDZ1 fusion protein
binding. (C) Summary of NHERF PDZ1-binding preferences at the
final four amino acid positions of target proteins based on single amino
acid substitution studies of the b2 receptor tail. The optimal amino acid
for each position is shown in the first line of the table. ‘‘Good’’ means
that the given change causes less than a twofold loss in NHERF PDZ1
binding relative to the optimal amino acid at that position, whereas
‘‘marginal’’ means that the given change causes more than a twofold
but less than a 10-fold decrease in binding. ‘‘Poor’’ means that the given
change leads to a .10-fold decrease in NHERF PDZ1 binding. The
results are representative of two to four independent determinations
for binding to each mutant tail.
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Previous studies revealed that mutation to alanine at the 22
or 23 positions of the b2 receptor tail significantly inhibits
NHERF binding but that mutation to alanine at the 21
position has no effect (10). Further mutations at the 21, 22,
and 23 positions (Fig. 1B) revealed that aspartate is markedly
better than any other amino acid examined at the 23 position
but that threonine is slightly better than serine at the 22
position. There is a slight preference at the 21 position for
basic residues over neutral or acidic residues (arginine is better
than leucine, and leucine is better than glutamate), but the
difference is less than a twofold change in NHERF binding
either way compared with the wild-type b2 receptor tail.
Mutation to aspartate at the 22 position results in a complete
loss of NHERF binding, suggesting that phosphorylation of
this site in vivo is likely to inhibit the binding of NHERF to the
b2 receptor. Interestingly, this serine (Ser411) is a substrate for
phosphorylation by the G protein-coupled receptor kinase
GRK5 (14). The effects of point mutations at each of the final
four positions of the b2 receptor tail are summarized in Fig. 1C.
Using primers based on GenBank accession no. Z50150, a
close relative of NHERF was cloned from a human lung cDNA
library. This species will be referred to here as ‘‘NHERF-2.’’
The two PDZ domains of NHERF-2, like the two PDZ
domains of NHERF, exhibit '60% identity with each other
and 20–30% identity with the PDZ domains of other proteins
such as PSD-95 and Dlg. In place of the G-L-G-F sequence
found at the core of the earliest characterized PDZ domains,
the NHERF PDZ domains contain the sequence G-Y-G-F. An
alignment of the NHERF and NHERF-2 PDZ domains is
shown in Fig. 2A. Analysis of the binding of the b2 receptor tail
to NHERF-2 revealed that the receptor tail binds to full-length
NHERF-2 and to the first NHERF-2 PDZ domain but not to
the second PDZ domain (Fig. 2B). These findings are identical
to the situation for b2 receptor tail binding to NHERF (10).
NHERF and NHERF-2 also exhibit a very similar pattern of
preferences for the panel of b2 receptor tail mutants presented
in Fig. 1 (data not shown).
Database searches for other proteins containing consensus
C-terminal sequences appropriate for interaction with the first
PDZ domain of the NHERF proteins yield a number of
intracellular proteins. Some of these proteins are listed in
Table 1. The list of potential NHERF-binding partners in-
cludes several proteins that are the products of known human
disease genes, such as CFTR and the Menke’s disease gene
protein (MNK). The list also includes a number of transmem-
brane receptors. In addition to the b2-adrenergic receptor,
which is known to bind to NHERF in an agonist-dependent
fashion in whole cells (10), the platelet-derived growth factor
receptor and the P2Y1-purinergic receptor represent potential
cellular-binding partners for the NHERF proteins.
The idea that binding partners for the NHERF proteins may
be identified based on the presence of the C-terminal D-Sy
T-x-L motif was tested by preparing the C-terminal tails of the
P2Y1 and P2Y2 receptors as GST fusion proteins and exam-
ining their ability to bind NHERF in the overlay assay. These
two purinergic receptor subtypes exhibit 33% overall sequence
identity but are divergent at their C termini: the P2Y1 receptor
ends in a good motif for NHERF PDZ1 binding (D-T-S-L)
whereas the P2Y2 receptor ends in a motif that is less than
ideal owing to the lack of a hydroxyl-bearing amino acid at the
22 position (D-I-R-L). As shown in Fig. 3A, the P2Y1 receptor
tail exhibits robust binding of NHERF, whereas the P2Y2
receptor tail exhibits poor NHERF binding. The affinity of
NHERF PDZ1 for the P2Y1 receptor tail was quantified via
saturation-binding studies and compared with the NHERF-
binding affinity of the b2 receptor tail (Fig. 3B); the KD for b2
receptor tail binding to NHERF PDZ1 is 18 nM, whereas the
KD for P2Y1 receptor tail binding is 300 nM.
The hypothesis that interaction with the NHERF family of
proteins may be predicted from the presence of a C-terminal
FIG. 2. NHERF-2 exhibits structural and functional similarity to NHERF. (A) Alignment of NHERF and NHERF-2 PDZ domains. The first
(‘‘PDZ-1’’) and second (‘‘PDZ-2’’) PDZ domains of both human NHERF and human NHERF-2 are aligned, with conserved residues boxed and
shaded. The positions of the PDZ domains within the NHERF proteins are indicated by the numbers in parentheses at the end of each sequence.
The two PDZ-1 sequences exhibit 73% identity, whereas the two PDZ-2 sequences exhibit 70% identity. The PDZ-1 and PDZ-2 domains of each
protein are 60% identical to each other. (B) The b2 receptor tail binds to recombinant NHERF-2 fusion proteins on a blot overlay. The b2 receptor
tail expressed as a GST fusion protein was overlaid onto three blotted samples: full-length NHERF-2 (‘‘full’’), the N-terminal 121 amino acids of
NHERF-2, which contains the first PDZ domain (‘‘N-term’’), and the C-terminal 210 amino acids of NHERF-2, which contains the second PDZ
domain (‘‘C-term’’). As shown by the Coomassie-stained SDSyPAGE gel (Left), equal amounts of the three fusion proteins were loaded. Overlays
of the blotted samples with the b2 receptor tail-GST (Right) revealed that the receptor tail binds specifically to full-length NHERF-2 and to the
N-terminal portion of NHERF-2 but not to the C-terminal portion. This experiment was performed three times with identical results.
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D-SyT-x-L motif was further tested by examining the binding
of NHERF to the tail of CFTR, which ends in D-T-R-L.
Blotted CFTR tail fusion protein exhibited robust and specific
binding of overlaid NHERF PDZ1 (Fig. 4A). The ability of
full-length NHERF to interact with full-length CFTR was
tested by in vitro translating full-length CFTR in the presence
of [35S]methionine and overlaying it onto blotted full-length
NHERF (Fig. 4B). Full-length CFTR bound avidly to
NHERF, as did the C-terminal tail of CFTR when assayed
separately. Conversely, neither the N-terminal portion of
CFTR nor a C-terminally truncated mutant CFTR (K1468X)
exhibited detectable binding to NHERF. CFTR tail bound not
only to recombinantly expressed NHERF but also to native
NHERF from differentiated airway epithelial cells. As shown
in Fig. 4C, a Triton X-100 soluble fraction derived from
cultured airway epithelia revealed a band of appropriate
molecular mass (50 kDa) when probed with either an anti-
NHERF antibody (10) or with 32P-labeled CFTR C-terminal
fusion protein.
DISCUSSION
The results presented here demonstrate that the first PDZ
domain of NHERF family proteins binds to target proteins
which terminate in the C-terminal motif D-SyT-x-L. The first
PDZ protein for which a preferred C-terminal motif was
identified was PSD-95, which recognizes the motif TyS-x-V at
the C terminus of target proteins (4). The motif recognized by
NHERF is distinct in that leucine is strongly preferred over
valine at the terminal position and aspartate is preferred at the
FIG. 3. The P2Y1 receptor tail binds to the first PDZ domain of NHERF, though with lower affinity than the b2-adrenergic receptor tail. (A)
The first PDZ domain of NHERF binds well to the b2 receptor tail, moderately to the P2Y1 receptor tail, and poorly to the P2Y2 receptor tail.
Equal amounts of the three fusion proteins (25 mg), along with control GST (Left lane), were run on an SDSyPAGE gel, blotted, and overlaid with
NHERF PDZ1 fusion protein (50 nM). This experiment was performed twice with identical results. (B) Determination of the binding affinity of
NHERF for the b2 receptor and P2Y1 receptor tails. Equal amounts of b2 receptor tail GST fusion protein or P2Y1 receptor tail GST fusion protein
(25 mg) were run on SDSyPAGE gels, blotted, and overlaid with six different concentrations of purified S-tagged NHERF fusion protein. The x-axis
is plotted as a logarithmic scale of the concentration of NHERF PDZ1 fusion protein, and the y-axis represents the relative amount of NHERF
PDZ1 binding expressed as a percentage of the binding observed at the highest NHERF PDZ1 concentration (1 mM in the case of the b2 receptor,
3 mM in the case of the P2Y1 receptor). The estimated KD for NHERF binding to the b2 receptor tail is 18 nM, whereas the estimate for NHERF
binding to the P2Y1 receptor tail is 300 nM. Each point and error bar represents the mean 6 SEM for three independent determinations.
Table 1. Potential NHERF-binding proteins
Receptors C-terminal motif
Beta-2 adrenergic receptor D-S-L-L
Purinergic P2Y1 receptor D-T-S-L
Platelet-derived growth factor receptor D-S-F-L
Transporters
Cystic fibrosis transmembrane regulator D-T-R-L
Copper transporter (Menke’s disease gene) D-T-A-L
Endomembrane proton pump, 58 kDa subunit D-T-A-L
Other Proteins
Phospholipase C-beta 1 D-T-P-L
Podocalyxin D-T-H-L
Kunjin virus-specified protein D-T-V-L
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23 position. Screening of peptide libraries has helped to define
the binding partner preferences of a number of PDZ domains
(5), and at the present time, no other PDZ domain has been
reported to have exactly the same preferences as the first PDZ
domain of the NHERF proteins. Thus, it is likely that the first
NHERF PDZ domain binds to a unique set of intracellular
partners that does not significantly overlap with the sets of
proteins bound by other PDZ domains.
The nomenclature of the NHERF family of proteins is
currently somewhat confusing. NHERF was originally purified
and cloned from rabbit tissue (8). Human NHERF was
recently cloned (15–16) and termed ‘‘hNHERF’’ (human
NHERF) (16) or ‘‘ERM-binding protein 50’’ (15) because it
was found to bind to the ERM family of actin-binding proteins
(ezrin, radixin, and moesin). NHERF-2, the close relative of
NHERF reported in the present manuscript, also has been
cloned recently by three independent groups who have given
the protein three different names: ‘‘TKA-1’’ (Seedorf and
Ullrich, unpublished data; GenBank accession no. Z50150),
‘‘E3KARP’’ (9), and ‘‘SIP-1’’ (11). To simplify the nomencla-
ture in this area, we propose to call this species NHERF-2
because it is closely related to NHERF (52% sequence iden-
tity) and has been shown to regulate NHE3 (9). NHERF-2
(GenBank accession no. AF035771) is essentially identical to
TKA-1 and E3KARP and is also identical to SIP-1 except for
a 33-bp insertion that is present in NHERF-2 but not in SIP-1.
It is likely that NHERF-2 and SIP-1 represent alternatively
spliced variants of the same gene.
The finding that NHERF and NHERF-2 both recognize the
motif D-SyT-x-L at the C terminus of target proteins is of
interest because NHERF-2 has been identified as a binding
partner for two proteins which contain variants of the motif:
the platelet-derived growth factor (PDGF) receptor (Seedorf
and Ullrich, unpublished data; GenBank accession no.
Z50150) and the testis-determining factor SRY (11). The last
four amino acids of human PDGF-A and PDGF-B receptors
are D-S-F-L, consistent with the C-terminal motif determined
in the present study to be optimal for NHERF PDZ1 binding.
Similarly, human SRY terminates in W-T-K-L, a C-terminal
motif that would be predicted from our mutagenesis studies to
bind NHERF-family proteins with a reasonable affinity.
The work described in the present report not only explains
the interaction of NHERF family proteins with two previously
identified binding partners, it also identifies two new potential
cellular NHERF-associated proteins: the P2Y1 receptor and
CFTR. Although the affinity of NHERF for the tail of the
P2Y1 receptor is .10-fold lower than its affinity for the tail of
the b2 receptor, this interaction could still potentially be of
physiological relevance given the abundance of NHERF in
some cell types. We have performed quantitative Western-
blotting studies, which indicate that NHERF represents 0.005–
0.01% of the total protein in crude kidney tissue (data not
shown). This result corresponds to a likely average intracellular
NHERF concentration of 500 nM to 1 mM (see Materials and
Methods for an explanation of the calculations behind these
estimates). NHERF may thus potentially bind to the P2Y1
receptor in a manner that is of physiological interest, and such
an interaction may have relevance for recent observations that
agonist stimulation of P2Y1 receptors can lead in some
instances to physiological responses that are independent of G
protein activation (17).
The interaction of NHERF with CFTR also may be of
physiological interest. Mutations in CFTR cause cystic fibrosis
(18). CFTR is a chloride channel, but some cellular actions of
CFTR are believed to be independent of its channel activity
(19–22). NHERF joins syntaxin (23) on a short list of CFTR-
interacting proteins that might potentially mediate some of
these channel-independent actions of CFTR. Interestingly, a
naturally occurring truncation of the tail of CFTR (S1455X)
has been recently reported (24). This mutation deletes the
NHERF-binding motif characterized in the present study and
produces an interesting clinical phenotype, with subjects ex-
hibiting elevated sweat chloride concentrations but no other
manifestations of cystic fibrosis. These findings suggest that the
binding of NHERF or NHERF-related proteins to the tail of
CFTR may be important for some aspects of CFTR function.
In summary, the motif D-SyT-x-L at the end of the b2
receptor is necessary for high affinity interaction with the first
PDZ domain of the NHERF proteins. The presence of this
motif at the C terminus of proteins is a useful indicator of
potential NHERF binding, as we have shown here in verifying
that the C termini of the P2Y1 receptor and CFTR bind to
NHERF. Consensus NHERF-binding motifs are found at the
C termini of many intracellular proteins. The variety of
proteins possessing C termini appropriate for high-affinity
binding to NHERF and NHERF-2 suggests that the NHERF
proteins may be multifunctional adaptor proteins involved in
many diverse aspects of cellular signaling.
FIG. 4. NHERF associates with CFTR tail and full-length CFTR.
(A) NHERF PDZ1 binds equally well to the tails of the b2 receptor
and CFTR expressed as fusion proteins but does not bind detectably
to control GST. Approximately 25 mg of each protein was run on an
SDSyPAGE gel, blotted, and then overlaid with 50 nM NHERF PDZ1
fusion protein. This experiment was performed twice with identical
results. (B) Full-length CFTR binds to full-length NHERF. In vitro
translated 35S-labeled probes of either CFTR C terminus (‘‘CFTR-
CT’’), CFTR N terminus (‘‘CFTR-NT’’), full-length CFTR (‘‘CFTR-
Full), or a truncated CFTR (’’K1468X‘‘) were overlaid onto blot strips
containing '10 mg of purified full-length NHERF fusion protein.
Full-length CFTR and CFTR C terminus bound avidly to the NHERF
but CFTR N terminus and CFTR K1468X did not detectably bind. (C)
An airway epithelial protein consistent with the size of NHERF is
recognized by the anti-NHERF antibody and by the C terminus of
CFTR. Soluble fractions of differentiated airway cells were stained
with Coomassie blue and probed with an anti-NHERF antibody or
with a 32P-phosphorylated C-terminal fusion protein of CFTR. The
antibody and the C-terminal probe both recognized a band of identical
size in the soluble fraction of airway proteins consistent with the
expected size of NHERF.
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Note Added in Proof. While this manuscript was under review, Wang
et al. (25) reported an affinity selection characterization of NHERF
PDZ domain-binding preferences and the interaction of NHERF with
CFTR.
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